Full Press Release Details
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib in China.
ZLAB
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib in China
Key Takeaway: Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib in China
Price reaction · baseline $58.75 (2022-02-16 close) · hit after-hours · clean, no other ZLAB news in the window
day 0 close · peak
-3.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.2%
average across 15 past catalysts
Cash runway
~28 mo
Low dilution risk
Lead asset
ZL-1310
Phase 3 · Small-cell Lung Cancer